Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + paclitaxel + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a multi-agent chemotherapy and targeted therapy regimen used primarily for the treatment of HER2-positive breast cancer. The combination includes: - Cyclophosphamide (an alkylating agent that interferes with DNA replication) - Epirubicin (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - Paclitaxel (a taxane that stabilizes microtubules, inhibiting cell division) - Pertuzumab and trastuzumab (monoclonal antibodies targeting the human epidermal growth factor receptor 2 [HER2], blocking its signaling and inducing antibody-dependent cellular cytotoxicity). This regimen is typically used in neoadjuvant or adjuvant settings for early, locally advanced, or metastatic HER2-positive breast cancer. The addition of pertuzumab and trastuzumab provides dual HER2 blockade, which has been shown to improve pathological complete response rates compared to chemotherapy alone or single-agent anti-HER2 therapy[1][2][5][6].
- Other names
- EC-PPHcyclophosphamide/epirubicin/paclitaxel/pertuzumab/trastuzumab
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + paclitaxel + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + paclitaxel + pertuzumab + trastuzumab.